Publications by authors named "Mark Carlton"

Claim this Profile
N
NETSseq reveals inflammatory and aging mechanisms in distinct cell types, driving cerebellar decline in ataxia telangiectasia.
Giuliano G Stirparo, Xiao Xu, Toni Thompson, Keith Page, Jenna R M Harvey, Mark B Carlton

Front Neurosci· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural insights into the high basal activity and inverse agonism of the orphan receptor GPR6 implicated in Parkinson's disease.
Mahta Barekatain, Linda C Johansson, Jordy H Lam, Hao Chang, Anastasiia V Sadybekov, Mark B L Carlton

Sci Signal· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial.
Nicola L Brice, Mark Carlton, David H Margolin, Martin Bexon, Kim L Matthews

EClinicalMedicine· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment.
Roland W Bürli, Kevin J Doyle, Louise Dickson, Anna Rowland, Kim Matthews, Mark Carlton

ACS Med Chem Lett· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist.
Angela Glen, Roland W Bürli, David Livermore, William Buffham, Stephanie Merison, Mark B Carlton

Bioorg Med Chem Lett· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Luvadaxistat: A Novel Potent and Selective D-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia.
Rosa Fradley, Pascal Goetghebeur, David Miller, Russell Burley, Sarah Almond, Mark Carlton

Neurochem Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Luvadaxistat: A Novel Potent and Selective D-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia.
Rosa Fradley, Pascal Goetghebeur, David Miller, Russell Burley, Sarah Almond, Mark Carlton

Neurochem Res· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of , a Novel Brain-Penetrant α6-Containing Nicotinic Receptor Antagonist for the Modulation of Motor Dysfunction.
Louisa A Christie, Nicola L Brice, Anna Rowland, Louise Dickson, Rishi Anand, Mark Carlton

J Med Chem· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Characterization of Novel CNS-Penetrant GPR55 Agonists.
Richard C Hewer, Louisa A Christie, Kevin J Doyle, Xiao Xu, Maxine J Roberts, Mark Carlton

J Med Chem· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of : A Highly Potent, Selective, and CNS Penetrant mGluR Allosteric Agonist.
Louise Dickson, Martin Teall, Elodie Chevalier, Toni Cheung, Gemma M Liwicki, Mark Carlton

ACS Med Chem Lett· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The oDGal Mouse: A Novel, Physiologically Relevant Rodent Model of Sporadic Alzheimer's Disease.
Wayne Chadwick, Stuart Maudsley, William Hull, Enes Havolli, Eugene Boshoff, Mark Carlton

Int J Mol Sci· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterisation of C101248: A novel selective THIK-1 channel inhibitor for the modulation of microglial NLRP3-inflammasome.
Bernardino Ossola, Ali Rifat, Anna Rowland, Helen Hunter, Samuel Drinkall, Mark B Carlton

Neuropharmacology· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Pharmacological targeting of glutamatergic neurons within the brainstem for weight reduction.
Marc Schneeberger, Nicola L Brice, Kyle Pellegrino, Luca Parolari, Jordan T Shaked, Mark Carlton

Nat Metab· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological targeting of glutamatergic neurons within the brainstem for weight reduction.
Marc Schneeberger, Nicola L Brice, Kyle Pellegrino, Luca Parolari, Jordan T Shaked, Mark Carlton

Nat Metab· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I, First-in-Human, Healthy Volunteer Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN424, a Novel G Protein-Coupled Receptor 6 Inverse Agonist for Parkinson's Disease.
David H Margolin, Nicola L Brice, Antonia M Davidson, Kim L Matthews, Mark B L Carlton

J Pharmacol Exp Ther· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and SAR of novel GPR39 agonists and positive allosteric modulators.
Russell Burley, Richard C Hewer, Martin Teall, Louise Dickson, Bernardino Ossola, Mark Carlton

Bioorg Med Chem Lett· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058.
Pejman Sehatpour, Daniel C Javitt, Heloise M De Baun, Marlene Carlson, Anna Beloborodova, Mark B L Carlton

Neuropsychopharmacology· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson's Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate.
Huikai Sun, Holger Monenschein, Hans H Schiffer, Holly A Reichard, Shota Kikuchi, Mark Beresford Lewis Carlton

J Med Chem· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease.
Nicola L Brice, Hans H Schiffer, Holger Monenschein, Victoria J Mulligan, Keith Page, Mark B Carlton

J Pharmacol Exp Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SIPA1L2 controls trafficking and local signaling of TrkB-containing amphisomes at presynaptic terminals.
Maria Andres-Alonso, Mohamed Raafet Ammar, Ioana Butnaru, Guilherme M Gomes, Gustavo Acuña Sanhueza, Mark Carlton

Nat Commun· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AKT signalling selectively regulates PINK1 mitophagy in SHSY5Y cells and human iPSC-derived neurons.
Marc P M Soutar, Liam Kempthorne, Shuichi Miyakawa, Emily Annuario, Daniela Melandri, Mark Carlton

Sci Rep· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the Target Engagement and D-Serine Biomarker Profiles of the D-Amino Acid Oxidase Inhibitors Sodium Benzoate and PGM030756.
Eimear Howley, Michael Bestwick, Rosa Fradley, Helen Harrison, Mathew Leveridge, Mark Carlton

Neurochem Res· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insulin-like peptide 5 is an orexigenic gastrointestinal hormone.
Johannes Grosse, Helen Heffron, Keith Burling, Mohammed Akhter Hossain, Abdella M Habib, Mark B L Carlton

Proc Natl Acad Sci U S A· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization and functional study of a cluster of four highly conserved orphan adhesion-GPCR in mouse.
Simone Prömel, Helen Waller-Evans, John Dixon, Dirk Zahn, William H Colledge, Mark B L Carlton

Dev Dyn· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The orphan adhesion-GPCR GPR126 is required for embryonic development in the mouse.
Helen Waller-Evans, Simone Prömel, Tobias Langenhan, John Dixon, Dirk Zahn, Mark B L Carlton

PLoS One· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis